Tercica (TRCA) is a small biotech which had an operating loss of $86 million last year on revenue of a little over $1 million. The year’s numbers have not been much better.
The company’s shares are up almost 25% after hours to $6.60 which would give the company a market cap over $270 million.
Why? Tercica signed a deal with Genentech (DNA) for the larger company to pay "up to" $53 million "to combine its Increlex with Genentech’s Nutropin, a growth hormone, to form a once-daily injectable treatment for children who don’t grow normally," according to CNN Money.
Phase 2 testing will not begin until next year, so the drug may or may not be approved by 2010.
A lot can happen in three years.
Douglas A. McIntyre
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
